Skip to search formSkip to main contentSkip to account menu

VeriStrat

A prognostic scoring system designed to predict non-small-cell lung cancer patients who will benefit from treatment with EGFR inhibitor therapy. A… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous…
e20510Background: Treatment (tx) options for patients (pts) with advanced SCC of the lung after progression on platinum-based… 
2015
2015
The value of proteomics in lung cancer.
Many studies have identified the prognostic and predictive value of proteins or peptides in lung cancer but most failed to… 
2014
2014
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
The role of EGF receptor (EGFR) inhibitors in the treatment of lung cancer without activating EGFR mutations has been a… 
2014
2014
VeriStrat validated in patients with non-small-cell lung cancer.
2012
2012
Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib.
e18096 Background: Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI TOF MS) was used to create… 
2011
2011
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.
After decades of empirical treatment, molecular subtypes of non-small-cell lung cancer (NSCLC) are now emerging that may enable… 
2011
2011
S1-4: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®).
Background: In EGF30008 the addition of lapatinib (La) to first-line treatment with letrozole (Le) significantly improved… 
2011
2011
PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).
TPS214 Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis (MALDI ToF MS) of NSCLC… 
Highly Cited
2010
Highly Cited
2010
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Background: We hypothesized that a serum proteomic profile predictive of survival benefit in non–small cell lung cancer patients… 
2008
2008
VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab
8008 Background: We previously developed a serum Matrix-Assisted Laser Desorption/Ionization- Time of Flight Mass Spectrometry… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)